ObsEva SA (OBSV)

[Frankestin]

https://www.obseva.com/wp-content/uploads/2022/03/ObsEva-Annual-Report-2021.pdf
Looking forward to 2022:
Thanks to the significant progress last year, we enter 2022 stronger and well-positioned for anticipated approvals. Looking ahead, we expect multiple catalysts, including:
? Yselty® for uterine fibroids:
– PUDFA target action date of September 13, 2022, as set by the FDA
– European Commission approval expected following December 2021 positive CHMP opinion
– Preparing for commercial launch
? Yselty® for endometriosis:
– Additional data from the post-treatment follow-up of the Phase 3 EDELWEISS 3 trial are
expected in 2Q 2022 and from the post-treatment follow-up of the extension study in 4Q 2022
? Ebopiprant:
– Discussing US clinical development with the FDA
? New opportunities:
– Exploring new indications, partnerships, and other strategic opportunities that enhance
ObsEva’s value and further our mission of bringing to market novel therapies that improve women’s health
? Financing: Furthering ongoing efforts to strengthen the balance sheet